Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of MT200605 in Healthy Subjects
NCT05948774Phase 1Completed
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Jan 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke comparing MT200605 with Placebo (2 arms). Primary endpoints: Adverse Events (AEs) at 4 weeks, Vital signs at 4 weeks and 3 more. Started Jul 2023; status: completed.
02
Drugs
MT200605
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05948774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948774.